Eli Lilly and Co.

Eli Lilly unit plans to buy feed-enzyme maker

January 24, 2012
Associated Press
Drugmaker Eli Lilly and Co.'s Elanco animal health division plans to buy a privately held maker of feed-enzyme products that improve poultry, egg and meat production.
More

Lechleiter bets history will repeat for Lilly

January 16, 2012
J.K. Wall
Eli Lilly and Co. CEO John Lechleiter keeps pouring more money into research and development, even as analysts note the payoff of such spending has dropped off 70 percent in the last decade.
More

Lilly's Zyprexa pact with health providers wins approval

January 12, 2012
Bloomberg News
Eli Lilly and Co. has won approval of a $4.5 million settlement with five union health funds and an insurer that alleged improper marketing of the company's best-selling medication, Zyprexa, raised their costs.
More

Pressure rises as Lilly tries squeeze play

January 9, 2012
J.K. Wall
Indianapolis-based Eli Lilly and Co. is now in the predicament of watching revenue fall as its patents on older products expire, even as the company needs to spend more money on marketing and research to boost sales of new drugs.
More

Boston lawsuit claims DES-breast cancer link

January 8, 2012
Associated Press
Fifty-three women from around the country are suing drug companies, including Eli Lilly and Co., who made and promoted DES for millions of pregnant women from about 1938 to the early 1970s.
More

Lilly's 2012 earnings forecast misses analyst estimates

January 5, 2012
Bloomberg News, Associated Press
Indianapolis-based Eli Lilly and Co. provided a 2012 earnings forecast Thursday morning that missed analyst estimates by a wide margin, sending shares down.
More

Lilly challenging Biogen patent in London lawsuit

January 5, 2012
Bloomberg News
Eli Lilly and Co. has sued Biogen Idec Inc. in a London court to revoke a European patent on a potential treatment for immune-system diseases.
More

Lilly losing dominance in diabetes treatmentRestricted Content

December 31, 2011
J.K. Wall
Eli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses on other products that have begun to sap the drugmaker's sales.
More

Patent expirations up pressure on Lilly

December 24, 2011
Eli Lilly and Co. lost patent protection on its $5-billion-a-year best-seller Zyprexa in October, plunging the company into the long-awaited zone of uncertainty that it calls “Years YZ.”
More

Lilly shares rise on possibility for Alzheimer’s drug

December 7, 2011
Bloomberg News
Eli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s experimental Alzheimer’s drug could double the share price.
More

Takeda, Lilly may face thousands of suits over Actos claims

December 1, 2011
Bloomberg News
Takeda Pharmaceutical Co. and marketing co-partner Eli Lilly and Co. may face as many as 10,000 lawsuits in U.S. courts over allegations that their Actos diabetes drug causes bladder cancer.
More

Drugmakers, pharmacists at odds

November 28, 2011
J.K. Wall
Indianapolis-based Eli Lilly and Co. recently rejected CVS Caremark’s demands for big price discounts on its insulins, leading CVS to kick Lilly’s insulins off its list of recommended drugs.
More

Lilly committed to China despite IP woes

November 21, 2011
J.K. Wall
Indianapolis-based Eli Lilly and Co. is one of several Western pharmaceutical firms that see China as a linchpin of growth in coming years, due to patent expirations and a slowdown in government reimbursements for prescription medicines in the U.S. and European markets.
More

Potential Lilly drug doubles good cholesterol

November 15, 2011
Bloomberg News
Eli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck & Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.
More

Potential Effient rival shows promise in study

November 14, 2011
Bloomberg News
A study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could give the companies entry to a $1 billion-plus market where Eli Lilly already competes.
More

Lilly files suit over flea medication sales from Australia

November 11, 2011
Scott Olson
The Indianapolis-based pharmaceutical firm claims an Australian veterinary clinic is infringing on its Comfortis flea medication's trademark by reselling it to U.S. consumers online.
More

Lilly, Amylin agree to end diabetes partnership

November 8, 2011
Bloomberg News, Associated Press
Amylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to end a decade-long diabetes partnership to resolve litigation. Amylin will make an upfront payment of $250 million to Lilly and future revenue-sharing payments of $1.2 billion plus interest.
More

Lilly, Bristol-Myers approved to market wider Erbitux use

November 7, 2011
Bloomberg News
Eli Lilly and Co. and Bristol-Myers Squibb Co. won U.S. approval to expand marketing of the cancer drug Erbitux for late-stage head and neck tumors.
More

Drug shortages hit Lilly, Endocyte

November 7, 2011
J.K. Wall
The nation’s shortage of certain drugs is threatening to affect research trials being conducted by Eli Lilly and Co. and Endocyte Inc.
More

Lilly hid Zyprexa's diabetes risks, family’s lawyer argues

November 2, 2011
Bloomberg News
Eli Lilly and Co. hid the diabetes risks of Zyprexa to protect sales, a lawyer for the family of a 20-year-old patient who died while taking the medicine told a jury in the first case to go to trial over the drug. The attorney asked jurors to award the family $40 million in compensatory damages.
More

Lilly loses British Supreme Court ruling over gene patent

November 2, 2011
Bloomberg News
The British Supreme Court ruled in favor of Human Genome Sciences Inc. in its dispute with Eli Lilly and Co. over the validity of a patent for a gene sequence that could be used to treat people with immune diseases.
More

Q&A

October 31, 2011
J.K. Wall
As an Eli Lilly and Co. lobbyist in Washington, D.C., Jay Bonitt is hoping the Congressional “super committee” charged with trimming the federal budget doesn’t turn to the Medicare prescription drug program, known as Part D, to do so. Bonitt, Lilly's vice president of federal affairs, said the program is under budget and helps spur drugmakers to further innovation.
More

Lilly fights view that fate hinges on Alzheimer's drugRestricted Content

October 29, 2011
Greg Andrews
Analysts have eyes on trial data for drug that could be a game-changer for the company.
More

Lilly wins European approval for new use of Alimta

October 28, 2011
J.K. Wall
Indianapolis-based drugmaker can now market lung cancer drug as a continuation maintenance therapy, potentially boosting sales after recent loss of patent on bestseller Zyprexa.
More

Zyprexa era comes to an end for LillyRestricted Content

October 27, 2011
 IBJ Staff
On Oct. 24, the U.S. Food and Drug Administration approved the first generic versions of Eli Lilly and Co.’s best-seller, ending 15 years of highly lucrative sales.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT